Skip to main content
Clinical Trials/NCT01757964
NCT01757964
Completed
Phase 1

Bacteriotherapy in Pediatric Inflammatory Bowel Disease

David Suskind1 site in 1 country13 target enrollmentDecember 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Inflammatory Bowel Disease
Sponsor
David Suskind
Enrollment
13
Locations
1
Primary Endpoint
Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease Activity Index (PCDAI) Scoring
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

In this study, the investigators want to see if Bacteriotherapy (also referred to as stool transplantation) improves the symptoms and decreases inflammation in children with Inflammatory Bowel Disease (IBD). Examples of IBD are Crohn's Disease and Ulcerative Colitis. Additionally, researchers want to learn whether this experimental therapy delays the need for starting additional medications to treat pediatric IBD.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
January 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
David Suskind
Responsible Party
Sponsor Investigator
Principal Investigator

David Suskind

Associate Professor of Pediatrics

Seattle Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • Children ages 12-21 years old with a diagnosis of mild to moderate Ulcerative Colitis or Crohn's Disease
  • Willing parent to donate stool for the transplant

Exclusion Criteria

  • Severe Disease
  • History of intra-abdominal abscess, intra-abdominal fistula or stricturing
  • History of other systemic diseases
  • The patient has received TNF inhibitors to treat their IBD within two months of transplant

Outcomes

Primary Outcomes

Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease Activity Index (PCDAI) Scoring

Time Frame: 2 weeks

The primary outcome measure is based on estimating the responder rate. This is defined as the proportion of patients with response to therapy by a drop of 10 or more points in PUCAI/PCDAI scoring. PUCAI/PCDAI are validated activity indexes for pediatric Ulcerative colitis and Crohn's disease, respectively. PUCAI scoring ranges from 0 to 85, with disease remission less than 10, mild disease activity between 10 - 35, moderate disease activity from 35 - 65, and severe disease activity above 65. PCDAI scoring ranges from 0 to 100; with remission being less than 10, mild disease from 10 to 30, and moderate to severe disease greater than 30.

Study Sites (1)

Loading locations...

Similar Trials